Abstract
Dupilumab is a monoclonal antibody that inhibits IL-4 and IL-13 signaling by targeting the IL-4 receptor a-subunit and is currently approved for treatment of atopic dermatitis (AD), asthma, and nasal polyposis. Currently, a single case report describes tolerance to foods which previously caused anaphylaxis after starting dupilumab treatment. However, to our knowledge the effect of dupilumab on serologic markers of FA has not been described.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
